Table 2.
Phosphorylation of MAPK and cancer-specific survival in validation cohort patients undergoing potentially curative resection of colorectal cancer (n = 801)
| Nuclear | Cytoplasmic | |||||
|---|---|---|---|---|---|---|
| N (%) | 10 yr CSS (SE) | P | N (%) | 10 yr CSS (SE) | P | |
| pERK1/2 | ||||||
| Weak activation | 327 (41) | 64 (3) | 0.037* | 379 (47) | 65 (3) | 0.047* |
| Strong activation | 474 (59) | 72 (2) | 422 (53) | 72 (2) | ||
| p-p38MAPK | ||||||
| Weak activation | 251 (31) | 65 (3) | 0.236 | 380 (47) | 66 (3) | 0.268 |
| Strong activation | 550 (69) | 70 (2) | 421 (53) | 71 (2) | ||
| C ombined pERK/p-p38 score | ||||||
| Both weak or one strong | 427 (53) | 64 (2) | 0.005* | 536 (67) | 65 (2) | 0.01* |
| Both strong | 374 (47) | 74 (2) | 265 (33) | 76 (3) | ||
*Significant difference p < 0.05